Phase III STELLAR clinical study results have demonstrated that the combination of eflornithine and lomustine achieved clinically meaningful improvements in overall survival and progression-free survival compared to lomustine alone in patients with recurrent IDH mutant, grade 3 astrocytoma.Â
Ben Ho ParkSara TolaneyBen Ho Park and Sara M. Tolaney will receive American Association for Cancer Research awards at the the San Antonio Breast Cancer Symposium Dec. 9-13 for their contributions to breast cancer research.Â
FDA approved Poherdy (pertuzumab-dpzb) as an interchangeable biosimilar to Perjeta (pertuzumab). This is the first approval of a biosimilar for Perjeta.
Paige Aiello has joined The Barbara Ann Karmanos Cancer Institute as a breast surgeon and member of the Breast Cancer Multidisciplinary Team.
Enhertu (fam-trastuzumab deruxtecan-nxki) demonstrated a highly statistically significant and clinically meaningful improvement in invasive disease-free survival in patients with a high risk of disease recurrence, according to results from DESTINY-Breast05 phase III trial.
Positive results from the DESTINY-Breast11 phase III trial showed Enhertu (fam-trastuzumab deruxtecan-nxki) followed by paclitaxel, trastuzumab, and pertuzumab in the neoadjuvant setting demonstrated a statistically significant and clinically meaningful improvement in the pathologic complete response rate.
Two years of adjuvant Verzenio (abemaciclib) plus endocrine therapy reduced the risk of death by 15.8% versus ET alone and resulted in sustained long-term improvements in invasive disease-free survival and distant relapse-free survival, in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative, node-positive, high-risk early breast cancer, according to the primary overall survival analysis of the phase III monarchE trial.
Armando E. Giuliano will receive the William L. McGuire Memorial Lecture Award during the 2025 San Antonio Breast Cancer Symposium, to be held Dec. 9-12 at the Henry B. Gonzalez Convention Center in San Antonio.
The phase III HER2CLIMB-05 trial of first-line combination therapy with the tyrosine kinase inhibitor Tukysa in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer has met its primary endpoint.Â
Positive high-level results showed Enhertu (fam-trastuzumab deruxtecan-nxki) demonstrated a highly statistically significant and clinically meaningful improvement in invasive disease-free survival versus trastuzumab emtansine in patients with HER2-positive early breast cancer with residual invasive disease in the breast or axillary lymph nodes after neoadjuvant treatment and a high-risk of disease recurrence, according to a planned interim analysis of the DESTINY-Breast05 phase III trial.Â
